Cara Therapeutics Financials
| 69C Stock | EUR 4.84 0.00 0.00% |
Cara |
Understanding current and past Cara Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cara Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Cara Therapeutics' assets may result in an increase in income on the income statement.
Cara Therapeutics Stock Summary
Cara Therapeutics competes with Novo Nordisk, CSL, CSL, Mercedes-Benz Group, and Vertex Pharmaceuticals. Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 55 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | US1407551092 |
| Business Address | 4 Stamford Plaza, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.caratherapeutics.com |
| Phone | 203 406 3700 |
| Currency | EUR - Euro |
You should never invest in Cara Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cara Stock, because this is throwing your money away. Analyzing the key information contained in Cara Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cara Therapeutics Key Financial Ratios
There are many critical financial ratios that Cara Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cara Therapeutics reports annually and quarterly.| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 | |||
| Target Price | 26.33 | |||
| Number Of Employees | 84 | |||
| Beta | 0.96 |
Cara Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cara Therapeutics's current stock value. Our valuation model uses many indicators to compare Cara Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cara Therapeutics competition to find correlations between indicators driving Cara Therapeutics's intrinsic value. More Info.Cara Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cara Therapeutics' earnings, one of the primary drivers of an investment's value.Cara Therapeutics Systematic Risk
Cara Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cara Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Cara Therapeutics correlated with the market. If Beta is less than 0 Cara Therapeutics generally moves in the opposite direction as compared to the market. If Cara Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cara Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cara Therapeutics is generally in the same direction as the market. If Beta > 1 Cara Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Cara Therapeutics January 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cara Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cara Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cara Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Cara Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cara Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.22 | |||
| Information Ratio | 0.1605 | |||
| Maximum Drawdown | 52.02 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 15.13 |
Complementary Tools for Cara Stock analysis
When running Cara Therapeutics' price analysis, check to measure Cara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutics is operating at the current time. Most of Cara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutics' price. Additionally, you may evaluate how the addition of Cara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |